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Abstract
Chromosomal rearrangements involving the EVI1 proto-oncogene are a recurrent finding in myeloid leukemias and are
indicative of a poor prognosis. Rearrangements of the EVI1 locus are often associated with monosomy 7 or cytogenetic
detectable deletions of part of 7q. As EVI1 overexpression alone is not sufficient to induce leukemia, loss of a 7q tumour
suppressor gene might be a required cooperating event. To test this hypothesis, we performed high-resolution array
comparative genomic hybridization analysis of twelve EVI1 overexpressing patients and three EVI1 deregulated cell lines to
search for 7q submicroscopic deletions. This analysis lead to the delineation of two critical regions, one of 0.39 Mb on 7q35
containing the CNTNAP2 gene and one of 1.33 Mb on chromosome bands 7q35–q36 comprising nine genes in EVI1
deregulated cell lines. These findings open the way to further studies aimed at identifying the culprit EVI1 implicated
tumour suppressor genes on 7q.
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Introduction
Chromosomal rearrangements involving chromosome band
3q26, such as translocations with various partner chromosomes
or inversions of chromosome 3 are a recurrent finding in myeloid
leukemias [1]. These aberrations contribute to the ectopic
expression of the EVI1 proto-oncogene. EVI1 transcriptional
activation has been reported in up to 10% of myeloid leukemia
patients, even in the absence of 3q26 rearrangements, and is an
independent indicator of adverse prognosis [2].
Retroviral integration experiments have shown that EVI1
overexpression alone is not sufficient to cause leukemia, indicating
that cooperative effects are necessary for malignant transformation
[3,4]. Interestingly, over fifty percent of the 3q26 rearranged
leukemias also display chromosomal abnormalities involving
chromosome 7, such as monosomy 7 or deletion of part of 7q [5].
This association alludes to the existence of a 7q tumour suppressor
gene, which when deleted acts in concert with EVI1 overexpression
to induce malignant transformation. We performed high-resolution
array comparative genomic hybridization (CGH) analysis to search
for 7q submicroscopic deletions in EVI1 deregulated leukemia
patients in order to identify candidate 7q tumour suppressor genes.
Materials and Methods
Patients and Cell Lines
Diagnostic bone marrow samples of twelve myeloid leukemia
samples and remission bone marrow samples of two patients (case
7 and case 8) were included in the study. Fluorescence in situ
hybridization (FISH) for detection of EVI1 rearrangement and
reverse transcription quantitative PCR (RT-qPCR) for detection
of EVI1 ectopic expression was performed as previously described
[6]. The study was approved by the ethics committee of the Ghent
University Hospital (2003/273).
Three EVI1 rearranged cell lines, Kasumi-3, MUTZ-3 and
UCSD-AML1 were also included in the study [7,8]. For the cell
lines culture conditions were as follows, for Kasumi-3 RPMI-1640
medium (Invitrogen, Belgium) was supplemented with 15% foetal
calf serum, 1% penicillin/streptomycin, 1% kanamycin, 1%
glutamine, 2% HEPES (1 M), 1% sodiumpyruvate (100 nM)
and 0.1% beta-mercapto ethanol (50 nM). For MUTZ-3, the used
medium contained an extra 10% of the supernatant of the 5637
urinary bladder carcinoma cell line [9] and 10 ng/ml of GM-CSF
(Promocell, UK). For the UCSD-AML1 cell line, the used medium
contained an additional 10 ng/ml of GM-CSF (Promocell, UK).
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results are described in Table 1.
Array CGH
DNA of patient samples and cell lines was isolated using the
QIAamp DNA mini kit (Qiagen, Belgium) or the Puregene Cell
kit (Gentra Systems, Belgium) according to the manufacturer’s
descriptions. Array CGH analysis for submicroscopic 7q deletions
was performed on a 44K custom array (Agilent technologies,
Belgium) covering the entire chromosome 7 with a probe spacing of
1 oligonucleotide every 3 kb, according to the manufacturer’s
descriptions. In brief, DNA (400 ng) was labelled using the BioPrime
Array CGH genomic labelling system (Invitrogen, Belgium) using
Cy5 (control DNA; Promega, Belgium) and Cy3 (patient sample or
cell line) labelled dCTPs (GE Healthcare, Belgium). Following
labelling, hybridization, and washing of the slides, arrays were
scanned using an Agilent DNA Microarray Scanner, quantified with
Feature Extraction software 10.1 and data were further analyzed
with arrayCGHbase[10] usinga circularbinarysegmentation (CBS)
algorithm taken into consideration log2 ratios of neighbouring
probes [11]. Deletions were called heterozygous when CBS ratios
were #20.5 and a deletion was considered putatively homozygous
when the CBS ratios were #21.2. Common copy number
variations (CNVs) present in the Database of Genomic Variants
(www.projects.tcag.ca/variation) were excluded from analysis.
Fluorescence In Situ Hybridization
To confirm the overlapping deletions found in the cell lines
Kasumi-3, UCSD-AML1 and MUTZ-3 at 7q35-q36, FISH
analysis was performed as previously described [6]. FISH probes
were selected from the UCSC genome browser database (http://
genome.ucsc.edu) (Table 2).
CNTNAP2 Expression Analysis
Total RNA was extracted from total bone marrow samples of
thirty nine EVI1 overexpressing patients (nine with monosomy 7),
five normal bone marrow samples and two CD34
+ cell fractions,
using the miRNeasy kit (Qiagen, Belgium). cDNA was prepared
from 2 mg of total RNA with the iScript cDNA Synthesis Kit (Bio-
Rad, Belgium) according to the manufacturer’s descriptions and
RT-qPCR for the CNTNAP2 (forward: 59-TAGGACATGGA-
ACCCCAATG-39 and reverse: 59-ATCGATTTGGCTCATC-
TTGG-39) transcript was performed as previously described
[12,13]. The reference genes RPL13A (forward: 59-CCTGGAG-
GAGAAGAGGAAAGAGA-39 and reverse: 59-TTGAGGACC-
TCTGTGTATTTGTCAA-39) and YWHAZ (forward: 59-AC-
TTTTGGTACATTGTGGCTTCAA-39 and reverse: 59-CCGC-
CAGGACAAACCAGTAT-39) were used for normalisation of
the RT-qPCR data.
Table 1. Patient and cell line characteristics: diagnosis, karyotype and EVI1 FISH and RT-qPCR results.
Name Diagnosis* Karyotype
{ FISH EVI1
{ RT-qPCR EVI1
{
Kasumi-3 AML 46,XY,t(2;5)(p13;q33),t(3;7)(q26;q22),del(5)(q15),28,del(9)(q32),add(12)(p11),add(16)(q13),+mar[20] ++
MUTZ-3 AML 46,XY,t(1;3)(q43;q13),t(2;7)(q36;q36),inv(3)(q21q26),inv(7)(p15q36),t(12;22)(p13;q12)[20] ++
UCSD-AML1 AML 45,XX,t(2;22)(p13;q12),t(3;3)(q21;q26),27[20] ++
case 1 MDS 46,XX,t(3;8)(q26;q23)[13]/46,XX[1] ++
case 2 AML 47,XY,+8,inv(3)(q21q26),t(13;22)(q10;p10)[20] ++
case 3 AML 46,XY,t(3;21)(q26;q22),add(17)(p11.2)[12]/46,XY[5] ++
case 4 MDS 45,XY,add(1)(q13),t(3;21)(q26;q22),add(5)(q13),213,218,+22[10]/46,XY[6] ++
case 5 AML 46,XY,inv(3)(q21q26)[8]/46,XY[2] ++
case 6 AML 47,XX,t(9;11)(p22;q23),del(11)(p15),+21[8]/46,XX[12] 2 +
case 7 AML 46,XX,t(9;11)(p22;q23)[8]/46,XX[12] 2 +
case 8 AML 45,X,2X,t(9;11)(p22;q23)[12]/46,XX[6]/45,X, 2X[3] 2 +
case 9 AML 45,XY,inv(3)(q21q26), 27[17] ++
case 10 AML 46,XY,t(3;3)(q21;q26)[15] ++
case 11 AML 45,XX,add(3)(q26), 27[15] ++
case 12 MDS 45,XY,t(3;21)(q26;q22), 27[20] ++
Bold formatting indicates the 3q26 rearrangement.
*AML=acute myeloid leukemia and MDS=myelodysplastic syndrome.
{The chromosomal aberration implicating the EVI1 locus is indicated with bold formatting.
{Positive for EVI1 FISH/qRT-PCR=+and negative for EVI1 FISH/qRT-PCR=2.
doi:10.1371/journal.pone.0008676.t001
Table 2. Name and position of FISH probes.
Probe name Position start* Position end*
RP112114L10 142486383 142604687
RP112106C6 148240833 148415979
RP112171N15 141216856 141779639
RP112728K20 149582837 149731647
RP112418B24 146512768 146667113
RP1121123J16 146673416 146811717
RP42803F10 146336163 146439692
RP42777G9 146949516 147038612
RP11279O14 147671295 147818484
RP112452J20 151938144 152144780
RP112312C1 152459779 152639208
*UCSC genome browser database (http://genome.ucsc.edu).
doi:10.1371/journal.pone.0008676.t002
7q Deletions in EVI1 Leukemia
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Based on karyotyping and FISH analysis, two critical regions,
one on chromosome band 7q22 [14] and one on chromosome
bands 7q32–q35 [15], have been identified as the targets for 7q
deletions in myeloid leukemia. In this study, array CGH was
applied to search for deletions on chromosome 7 at ultra-high
resolution. Using this approach, we identified several submicro-
scopic 7p and 7q deletions in EVI1 overexpressing patients and cell
lines (Table 3 and Figure 1) including two critically deleted regions
on 7q35–q36 in EVI1 deregulated cell lines. These deletions were
confirmed using FISH (Figure 2).
Interestingly, in the Kasumi-3 cell line a 680 kb homozygous
deletion on 7q encompassing the CNTNAP2 gene was identified,
located within a 6.51 Mb heterozygous deleted region at 7q34–
q36. The observation of homozygous deletions has been of great
importance in tumour genetics as the deleted region often contains
putative tumour suppressor genes. In the MUTZ-3 cell line, a
4.83 Mb deletion was present within the same chromosomal
region, delineating a shortest region of overlap (SRO) of 1.33 Mb
(Figure 3) encompassing nine genes (Table 4). Interestingly, in the
UCSD-AML1 cell line a homozygous deletion of 0.39 Mb was
detected encompassing the CNTNAP2 gene, which delineated a
second SRO of 0.39 Mb on 7q35 (Figure 3).
CNTNAP2 is located in a common fragile site which is
inactivated in different types of cancers such as brain, ovarian
and breast tumours [16], and methylation of the promoter of this
gene has been described in pancreatic adenocarcinoma [17].
However, upon RT-qPCR analysis of the CNTNAP2 gene no
expression could be detected in normal bone marrow samples,
CD34
+ cell fractions or EVI1 overexpressing bone marrow
samples (data not shown), indicating that this gene is not a
straightforward candidate 7q tumour suppressor gene cooperating
with EVI1 overexpression.
Subsequent screening of twelve EVI1 overexpressing patient
samples with (3 cases) or without (9 cases) monosomy 7, revealed
no submicroscopic alterations within the above described SROs.
However, focal deletions in other genomic regions on chromo-
some arms 7p and 7q were detected.
Of interest is that both the Kasumi-3 and the MUTZ-3 cell line
display chromosomal rearrangements involving chromosome 7. It
is well known that small deletions can occur at chromosomal
breakpoints [18]. Therefore, the observed 4.83 Mb deletion at
7q36 in MUTZ-3 might have originated as a consequence of the
t(2;7)(q36;q36) and/or the inv(7)(p15q36) present in this cell line.
Of the nine genes located within the 1.33 Mb SRO CUL1 and
EZH2 are the most promising candidates due to known function in
and association with cancer. The CUL1 gene encodes a protein
that, when associated with other proteins such as Skp1, forms the
Skp2 E3 ubiquitin ligase E3 complex involved in degradation of
different proteins [19]. In AML, the Skp2 complex has been
described to target the MEF transcription factor which induces
G1/S transition. Impairment of the Skp2 complex leads to a
decrease in MEF degradation thereby promoting cell proliferation
[20]. Deletion and mutation of other E3 ubiquitin ligase complex
members such as the F-box containing FBXW7 gene has already
Table 3. Array CGH results of chromosome 7 deletions.
Name Chromosomal position* Start - end (Mb) Size (Mb) Genes{
Kasumi-3 7p22 236995626743766 4,37 SDK1 (40)
7p222p15 7010834226480795 19,47 63
7q31.2 1164123042116584949 0,17 ST7
7q342q36 1421825892148693649 6,51 KEL, CNTNAP2
{, CUL1, EZH2 (48)
MUTZ-3 7q352q36 1473773252152205764 4,83 CNTNAP2, CUL1, EZH2 (61)
UCSD-AML1 7q11.22 69266162269318942 0.053 AUTS2
{
7q21.11 78183200278189877 0.007 MAGI2
{
7q35 1464827432146873269 0.391 CNTNAP2
{
case 2 7q34 1423514412142361904 0,01 KEL
case 3 7p22 403638924042650 0,01 SDK1
7p12 43592619243597672 0,01 STK17A
case 9 7q32.2 129076051–129078116 0.02 NRF1
{
Bold formatting indicates deletions on the 7q arm.
*Based upon the UCSC genome browser (http://genome.ucsc.edu/cgi-bin/hgGateway, NCBI Build 36.1).
{Between brackets is the total number of genes residing in the deleted area.
{Homozygous deletion.
doi:10.1371/journal.pone.0008676.t003
Figure 1. Overview of deletions in cell lines and patients. Chromosome view of chromosome 7 deletions in the cell lines Kasumi-3, MUTZ-3
and UCSD-AML1 and in cases 2, 3 and 9. Deletions are indicated using grey bars.
doi:10.1371/journal.pone.0008676.g001
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where it is associated with poor prognosis [21]. Moreover, in AML
loss-of-heterozygosity (LOH) of the EZH2 (polycomb group) gene
(enhancer of zest) was detected in 5 out of 21 patients [22].
However, further analyses such as mutation screening and
functional RNA interference screens [23] are needed to identify
the genes contributing to EVI1 leukemogenesis.
In addition to the regions described above, other 7q deletions in
the EVI1 overexpressing patients as well as in the UCSD-AML1
cell line were detected. In UCSD-AML1 two additional small 7q
deletions were observed, a 53 kb (7q11.22) and 7 kb (7q21.11)
deletion and containing the AUTS2 and MAGI2 genes respectively.
In case 2, a small deletion of 10 kb on 7q34 was observed
encompassing the KEL blood group gene. In Kasumi-3, this gene
was located in a larger deleted region of 6.51 Mb on 7q34–q36. In
case 9, a small homozygous deletion of 20 kb on 7q32.2 was
detected. Located in this region is the NRF1 gene for which
inactivating mutations have already been described in liver cancer
[24].
Besides the above mentioned 7q deletions, several 7p deletions
were also detected, some of which were common between different
patients and/or cell lines. In case 3, a small deletion of 10 kb on
7p22 was observed encompassing the SDK1 sphingosine depen-
dent protein kinase gene. In Kasumi-3, this gene was located in a
larger deleted region of 4.37 Mb on 7p22. As involvement of the
SDK1 gene in apoptosis has already been described [25], deletion
of this gene could lead to a decreased rate of cell death. For patient
3 deletion of the STK17A gene at 7p12 was detected. Deletion of
this pro-apoptotic gene had already been described in laryngeal
squamous cell carcinoma [26]. It should be noted that it is possible
that the above described small 7q and 7p deletions in patient
samples are not leukemogenic as no constitutional material of
these patients was available. In the remaining patient samples no
chromosome 7 deletions could be detected.
In conclusion, using high-resolution array CGH, we were able
to delineate two critical regions for 7q deletions in myeloid
leukemias that were not detectable using standard karyotyping.
Besides a 0.39 Mb SRO on 7q35 containing the CNTNAP2 gene,
we identified a 1.33 Mb region on chromosome bands 7q35–q36
containing nine putative tumour suppressor genes in EVI1
deregulated cell lines. Further analysis of these candidates is
warranted to investigate their role in EVI1 mediated malignant
Figure 2. FISH analysis of the 7q35–q36 deletions in cell lines. A), D) and G) FISH analysis on cytogenetically normal controls with probes
located within the 7q35–q36 deleted regions. B), E) and H) FISH analysis with probes located within the 7q35–q36 deleted regions on the cell lines
Kasumi-3 (B), UCSD-AML1 (E) and MUTZ-3 (H). C), F) and I) FISH analysis with probes just outside of the 7q35–q36 deleted regions on the cell lines
Kasumi-3 (C), UCSD-AML1 (F) and MUTZ-3 (I).
doi:10.1371/journal.pone.0008676.g002
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8676Figure 3. Array CGH profile of chromosome 7 (141 Mb–153 Mb) for Kasumi-3, MUTZ-3 and UCSD-AML1. A) Array CGH profile of
Kasumi-3, B) MUTZ-3 and C) UCSD-AML1 indicating the 0.39 Mb SRO on 7q35 and the 1.33 Mb SRO on chromosome bands 7q35–q36. Log2-ratios of
the clones are depicted by vertical dots corresponding to the respective genomic position (NCBI build 36). Deletions are shown in red. The SROs are
indicated with a purple box. The bottom of the figure shows the genomic position with an indication of known CNVs as present in the Database of
Genomic Variants (http://projects.tcag.ca/variation/). Regions of segmental duplication are displayed using black and grey boxes indicating identical
genomic regions. A screenshot of the UCSC Genome Browser (NCBI build 36, http://genome.ucsc.edu) shows an overview of the known RefSeq genes
in the 1.33 Mb critical region.
doi:10.1371/journal.pone.0008676.g003
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suppressor gene opens perspectives for novel treatment strategies
selectively restoring the expression of the deleted genes.
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